Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6PD74
UPID:
AAGAB_HUMAN
Alternative names:
-
Alternative UPACC:
Q6PD74; B4DG44; Q6FI86; Q7Z5X9; Q9H0P1; Q9HAK0
Background:
Alpha- and gamma-adaptin-binding protein p34 plays a crucial role in the endocytic recycling of growth factor receptors, including the EGFR. This protein's involvement in cellular trafficking underscores its importance in maintaining cellular function and communication.
Therapeutic significance:
The association of Alpha- and gamma-adaptin-binding protein p34 with Keratoderma, palmoplantar, punctate 1A, a dermatological disorder, highlights its potential as a target for therapeutic intervention. Understanding the role of this protein could open doors to potential therapeutic strategies.